Founded in 2013, Zebra Biologics is a biotech startup that focuses on discovering and developing next-generation human biologic drugs. The company utilizes a proprietary platform technology to efficiently and effectively identify fully human therapeutic biologics, such as antibodies, peptides, and proteins, from DNA-encoded combinatorial libraries. With an exclusive license to new technologies developed by Dr. Richard Lerner and his team at The Scripps Research Institute, Zebra plans to collaborate with pharmaceutical and biotechnology companies to bring a portfolio of "bio-superiors" antibodies into clinical development within the next 2-5 years. Their drug development process includes cellular function-based screening, enabling the treatment of various diseases including diabetes, obesity, cancer, and neurological disorders.